Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2023-0542 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sarcoma: Last Year's Practice Changing Papers.
Ann Surg Oncol
December 2024
Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Background: In 2023 and 2024, a wide variety of new studies have been published in the field of soft tissue sarcomas, representing the enormous heterogeneity of sarcoma histotypes, anatomical location, treatment variability, and biological behavior.
Patients And Methods: This article summarizes the, in our view, seven most important publications in the field that will have an impact on the surgical practice and future treatment strategies of our patients.
Results: In the last year, we gained more insight in the genetic background of patients with sarcoma from a large Australian study, which will have an impact on future counseling and screening of our patients.
TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group.
ESMO Open
August 2024
Fondazione IRCC Istituto Nazionale Tumori, Medical Oncology 2, Milan.
Background: This is a multicentre, single-arm, phase II study aimed at further exploring the activity of trabectedin as second-/further-line treatment in retroperitoneal leiomyosarcoma (LMS) and well-differentiated/dedifferentiated liposarcoma (LPS).
Materials And Methods: The primary endpoint was the growth modulation index (GMI) defined as the ratio between PFS under trabectedin (PFS) and during previous chemotherapy treatment: time to progression (TTP-1). Secondary endpoints were objective response rate (ORR) and PFS.
Progress in histology specific treatments in soft tissue sarcoma.
Expert Rev Anticancer Ther
September 2024
Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Article Synopsis
- Soft tissue sarcomas (STS) are a rare, diverse group of tumors usually treated with surgery, with preoperative radiotherapy often recommended for high-risk cases, particularly in the extremities.
- Neoadjuvant chemotherapy, especially using doxorubicin and ifosfamide, has shown success in treating STS located in limbs and trunk walls, while second-line treatments focus on the tumor's histology.
- Recent advancements in treatment, driven by clinical trials, highlight the need for more research to better understand the efficacy of chemotherapy, targeted therapies, and immunotherapy in STS and to identify patient biomarkers for optimal treatment outcomes.
Effectiveness of trabectedin for radiation-induced angiosarcoma of the breast refractory to several anticancer drugs.
J Dermatol
August 2024
Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma.
Ther Adv Med Oncol
January 2024
Medical Oncology Department, Fundación Jimenez Diaz University Hospital, Madrid, Spain.
Background And Objectives: Dimensional response is an unmet need in second lines of advanced soft tissue sarcomas (STS). Indeed, the three approved drugs, pazopanib, trabectedin, and eribulin, achieved an overall response rate (ORR) of less than 10%. This fact potentially hinders the options for fast symptomatic relief or surgical rescue.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!